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Abstract
Background Lubiprostone helps relieve constipation in
short-term 4-week studies. There are limited data on long-
term pharmacological treatment with lubiprostone for
chronic idiopathic constipation.
Aims To examine the long-term safety and effectiveness
of lubiprostone in patients with chronic idiopathic
constipation.
Methods In this prospective, multicenter, open-labeled
trial, 248 patients aged C18 years with chronic idiopathic
constipation were directed to take lubiprostone 24 mcg
BID as needed for 48 weeks. Patients were allowed to
decrease the dose in response to the perceived severity of
constipation and need for relief. Hematology and chemistry
proﬁles and assessment of constipation symptoms and its
severity were performed at all visits. Adverse events (AEs)
were recorded.
Results Of the 248 patients who entered the trial, 127
(51%) completed the trial. A dose reduction was observed
in 17% of the patients, resulting in an average study
medication exposure across the study of approximately 1.7
capsules (or approximately 40.8 mcg) per day. The most
common treatment-related AEs were nausea (19.8%),
diarrhea (9.7%), abdominal distension (6.9%), headache
(6.9%), and abdominal pain (5.2%). No deaths were
reported and of the 16 reported serious AEs, one was
considered possibly treatment related. Average changes in
serum electrolytes were not clinically relevant at any time
point during the study. On average, lubiprostone signiﬁ-
cantly (p\0.0001) reduced patient-reported constipation
severity, abdominal bloating, and abdominal discomfort
across 48 weeks when compared to baseline.
Conclusions During this 48-week open-label study,
lubiprostone was well tolerated. Bowel symptoms consis-
tently improved over 48 weeks in adult patients with
chronic idiopathic constipation.
Keywords Lubiprostone  Chronic idiopathic
constipation  Long-term safety  Effectiveness
Introduction
Constipation is a common complaint, with prevalence
estimates ranging from 2–28% in the United States; con-
stipation is also found more commonly in women and the
elderly [1–3]. In the United States, physician visits from
A. J. Lembo (&)
Division of Gastroenterology, Harvard Medical School,
330 Brookline Ave., DA-501, Boston, MA, USA
e-mail: alembo@bidmc.harvard.edu
J. F. Johanson
College of Medicine, University of Illinois, Rockford, IL, USA
e-mail: johnfj@uic.edu
H. P. Parkman




Division of Gastroenterology-Hepatology, Carver College
of Medicine, University of Iowa, Iowa City, IA, USA
e-mail: satish-rao@uiowa.edu
P. B. Miner Jr.
Oklahoma Foundation for Digestive Research,
Oklahoma City, OK, USA
e-mail: Philip-Miner@ouhsc.edu
R. Ueno
Sucampo Pharmaceuticals Inc., Bethesda, MD, USA
e-mail: rueno@sucampo.com
123
Dig Dis Sci (2011) 56:2639–2645
DOI 10.1007/s10620-011-1801-01958 to 1986 for constipation averaged 2.5 million per year
[1]. A more recent study by Martin and colleagues, using
data from 2001, found 5.7 million physician/emergency
room visits were constipation related [4]. However, these
data likely underestimate the problem, since only a
minority of people with constipation seek medical care
[5, 6].
The prevalence of chronic constipation and the growing
demand for treatment dictate the need for safe and effective
treatment options. Currently available interventions include
lifestyle changes and a broad range of over-the-counter
(OTC) and prescription medications. Studies of short-term
treatment with dietary ﬁber supplements and exercise have
demonstrated marginal effectiveness [7, 8]. Additionally,
while patients may note symptomatic short-term improve-
ment with the use of OTC medications (e.g., bulk laxatives,
osmotic laxatives, and stimulant laxatives), the current
approved indication for such agents does not support their
long-term use in patients with chronic constipation [9–11].
Lubiprostone, an activator of chloride channels (ClC-2),
is a member of a class of compounds called prostones, and
has been approved by the Federal Drug Administration
(FDA) as an agent for the treatment of chronic idiopathic
constipation. Activation of ClC-2 results in increased
chloride secretion with associated passive transport of
sodium and water across gastrointestinal mucosal epithelia,
thereby enhancing ﬂuid secretion into the intestinal lumen
and promoting intestinal transit [12–15].
Two recent clinical studies have demonstrated lubipro-
stone’s efﬁcacy in the short-term treatment of chronic idio-
pathic constipation [16, 17]. In a 4-week, randomized,
placebo-controlled trial involving 242 patients with chronic
idiopathic constipation, lubiprostone 24 mcg twice daily
(BID) signiﬁcantly increased the number of spontaneous
bowel movements (SBMs) compared with placebo (5.1–5.7
perweekforlubiprostonevs.2.8–3.5forplacebo[p\0.002])
[16]. Likewise, in a second 4-week trial involving 237
patientswithchronic idiopathicconstipation, lubiprostone 24
mcg BID increased the number of SBMs from a pretreat-
ment mean of 1.30 to 5.89 SBMs per week at Week 1, which
was signiﬁcantly greater than placebo (p\0.0001) [17].
The aim of the current study was to assess the safety and
effectiveness of lubiprostone 24 mcg BID taken open-label
as needed for 48 weeks in patients with chronic idiopathic
constipation.
Methods
Study Design and Patients
The study was conducted in accordance with the U.S. Code
of Federal Regulations on Good Clinical Practice,
consistent with the Declaration of Helsinki, and the Inter-
national Conference on Harmonisation (ICH). Prior to
enrollment, written informed consent was obtained from
each patient. The study protocol, informed consent form,
and volunteer information requirements (inclusion/exclu-
sion criteria) were approved by the Institutional Review
Boards of the participating centers.
In this prospective, 48-week, multicenter, open-label
study, patients were directed to take lubiprostone 24 mcg
BID or a lower dose (24 mcg QD) as needed, based on
their perceived severity of constipation and need for relief,
or at the investigator’s discretion in response to adverse
events (AEs). Following the treatment period, patients
were monitored for an additional 2 weeks. Patients were
enrolled either directly into the study (after a 2-week
baseline washout period) or immediately after completing
an independent randomized-withdrawal trial (Fig. 1). In the
randomized-withdrawal study, following 4 weeks of treat-
ment with lubiprostone 24 mcg BID, half of the patients
were randomized to receive placebo and the remaining
patients were continued on active treatment with lubipro-
stone for an additional 3 weeks [18]. Upon completion of
the randomized-withdrawal study, eligible patients were
enrolled into the open-label treatment phase reported here,
during which all patients were instructed to take lubipro-
stone 24 mcg BID for 48 weeks.
The study enrolled male and female patients
aged C18 years with C3 months of constipation, deﬁned as
an average of\3 SBMs/week and C1 of the following
symptoms with atleast 25% of bowelmovements: very hard
(little balls) and/or hard stools, a sensation of incomplete
evacuation, and/or straining at defecation. Patients were
directed not to change their lifestyle or diet during the study,
including exercise and ﬁber intake. Study exclusion criteria
included: documented mechanical obstruction, a megaco-
lon/megarectum, or a diagnosis of pseudo-obstruction;
known or suspected organic small or large bowel disorders;
evidence of secondary causes of constipation; hospitaliza-
tion for any gastrointestinal or abdominal surgery during the
3 months prior to study commencement; or any bowel
resection. Patients aged\50 years were required to have
had a ﬂexible sigmoidoscopy or colonoscopy performed
within the previous 5 years. For patients aged C50 years
and any participant for whom there was evidence of weight
loss, anemia, or rectal bleeding since the previous evalua-
tion, a barium enema with ﬂexible sigmoidoscopy or
colonoscopy was required. Female patients could not breast
feed or be pregnant, as conﬁrmed by a negative serum
pregnancy test at the baseline visit and at subsequent ofﬁce
visits during the treatment period.
Patients were directed to take lubiprostone 24 mcg BID
with food (usually breakfast and dinner) and at least 8 oz.
of water. However, the daily dose could be reduced at the
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123discretion of the investigator in response to exaggerated
pharmacodynamic events (e.g., diarrhea, or other treat-
ment-related AEs such as nausea). Patients who had been
routinely using a daily ﬁber supplement for C3 months
prior to baseline were allowed to continue use throughout
the study but were not allowed to change the dose or
administration schedule. Patients were prohibited from
taking other prescription or OTC medications for consti-
pation during the study period, including the baseline/
washout period. All other medications were permitted but
usage was documented; initiation and/or discontinuation of
medications after study initiation were limited to the extent
possible and at the discretion of the investigator. Study
investigators could authorize participants to administer the
following rescue medications if they had not experienced a
bowel movement for C3 consecutive days and felt they
needed relief: Dulcolax
 (bisacodyl, Boehringer Ingelheim
Consumer Healthcare, UK) suppository or, if unsuccessful,
a Fleet
 Enema (dibasic sodium phosphate and monobasic
sodium phosphate, C.B. Fleet Company, Incorp., Lynch-
burg, VA). If neither medication was effective, another
rescue medication could be prescribed for limited use at the
investigator’s discretion.
Safety and Patient-Reported Outcome Assessments
At the baseline visit prior to study enrollment, patients’
medical and constipation histories were taken. Baseline
constipation severity and symptoms (e.g., timing and
consistency of, and straining during, bowel movements)
were assessed via patient diary recordings during the pre-
ceding 2-week washout period. Patients underwent a
physical examination, including vital signs and body
weight, and laboratory testing (hematology, chemistries,
and urinalysis) at baseline and at weeks 12, 24, 36, and 48
during the treatment period.
Safety assessments consisted of AEs (recorded from the
time of the ﬁrst lubiprostone dose until the follow-up visit),
serious AEs (SAEs; recorded up to 7 days after the ﬁnal
lubiprostone dose), clinical laboratory evaluations, vital
signs, and physical examinations. Intensity (mild, moder-
ate, or severe) and relationship to study drug (unrelated,
possibly, probably, or deﬁnitely related) were recorded for
all AEs. Use of concomitant therapy was evaluated at every
study visit, and any concomitant therapy given as treatment
for a new condition or worsening of an existing condition
was considered an AE.
Patient-reported outcome assessments were comprised of
patient global assessments (severity of constipation; treat-
ment effectiveness) and abdominal assessments (percep-
tions of bloating and discomfort upon waking in the
morning). Patients were assessed at baseline, enrollment,
and each subsequent study visit. Study visits occurred every
6 weeks and alternated between ofﬁce and phone visits for a
total of 11 study visits over a 48-week treatment period,
with the last follow-up visit occurring at week 50. Severity
of constipation and abdominal symptoms were rated on a
5-point scale: 0 = absent; 1 = mild; 2 = moderate;
3 = severe; 4 = very severe. Treatment effectiveness was
also evaluated usinga 5-point scale: 0 = not at all effective;
1 = a little bit effective; 2 = moderately effective;
3 = quite a bit effective; 4 = extremely effective. These
same scales were used for the pivotal, 4-week randomized,
placebo-controlled lubiprostone studies [16, 17].
Fig. 1 Flow of participants
through each stage of the study.
Single asterisk One patient
hospitalized before receiving
study medication; one patient
lost to follow-up. Double
asterisk Two patients
discontinued the trial before
receiving study medication in
the open-labeled phase
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All patients who received C1 dose of lubiprostone during
the 48-week treatment period were evaluated for safety; a
subset of this population was analyzed for effectiveness.
Data from the most recent study visit were analyzed per the
study protocol. Approximately 300 patients with consti-
pation were planned for enrollment into the study with the
goal of completing 100 patients with 1 year of exposure to
lubiprostone. This sample size goal was based on ICH
recommendations [19] and was estimated to yield a 95%
chance of detecting events occurring at a rate of C1% in a
population.
Patient demographics and baseline characteristics were
summarized including constipation data using descriptive
statistics. Demographic differences between patients who
completed the study versus those who did not were ana-
lyzed using Fisher’s exact test, and changes in constipation
and abdominal symptom severity were assessed using
Wilcoxon matched-pair signed-rank tests.
Cumulative exposure to lubiprostone was expressed as
the sum of all dose administrations provided from the start
of treatment until the next visit, when capsule counts were
conducted. Average daily exposure was calculated as the
cumulative exposure divided by the number of days of
treatment in this interval.
AEs were summarized in terms of incidence, with the
incidence rates of AEs expressed as a percentage of the
number of safety-evaluable patients experiencing at least
one episode of the AE during the safety window (time from
ﬁrst to last dose of study medication plus 7 days). Inci-
dence rates of AEs, AEs assessed as at least possibly
related to the study medication, SAEs, and AEs reported
by C5% of patients were calculated. Patient-days were
calculated using date of last visit minus date of ﬁrst dose
plus 1 day. Nausea event rate was calculated using number
of nausea events divided by total patient days. Laboratory
test results were tabulated using descriptive statistics.
Descriptive statistics were used to evaluate mean changes
of continuous vital sign data at each visit. Paired t tests
were used to analyze the signiﬁcance of observed changes
in vital signs from baseline. For patient-reported parame-
ters, global assessments (severity of constipation and
treatment effectiveness) and abdominal assessments
(bloating and discomfort upon waking in the morning)
were summarized. Missing values for patient-reported
variables, including patient withdrawals, were not imputed.
Analyses of each time point were performed on the
observed cases for that time point. Analyses are broken
down by enrollment group and all subjects combined.
Changes in severity of constipation and abdominal symp-
toms from baseline through 48 weeks were analyzed via
Wilcoxon matched-pairs signed-ranks tests.
Results
Patients
Of the 250 patients enrolled in the study, 80 were recruited
from the randomized withdrawal study (4 weeks of treat-
ment followed by 3 weeks of randomized withdrawal)
[18], while 170 (lubiprostone-naive) were enrolled directly
into the current open-label treatment study. Of the 248
patients who began the study, 127 (51%) completed the
trial. The most common reasons for discontinuation were a
lack of effectiveness (17.7%), AEs (13.3%), and voluntary
withdrawal (9.3%; Fig. 1).
Two patients withdrew from the study prior to taking the
ﬁrst dose of lubiprostone. A comparison of the demo-
graphics revealed the two patient groups to be similar, and
the combined data are summarized in Table 1.
The mean daily dose of lubiprostone was consistent
throughout the trial (approximately 1.7 capsules/day), with
Table 1 Patient demographics at baseline (safety evaluable
population)













Age (years) 51.23 ± 13.90
Weight (lbs) 164.77 ± 33.58
Height (inches)* 65.71 ± 3.45
Number of SBMs/week* 1.33 ± 0.90
Average consistency of SBM
a,b 2.57 ± 0.86
Average degree of straining
b,c 2.24 ± 0.93
Constipation severity*
,c 2.94 ± 0.73
Abdominal bloating
c 2.10 ± 0.89
Abdominal discomfort
c 1.88 ± 0.92
SBM spontaneous bowel movement, SD standard deviation
* n = 247
a 0 = very loose; 1 = loose; 2 = normal; 3 = hard; 4 = very hard
b N = 207
c 0 = absent; 1 = mild; 2 = moderate; 3 = severe; 4 = very severe
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123a mean daily intake of 1.67 capsules at Week 48. Of the
patients, 17% of patients required a dose reduction of
lubiprostone, as determined by the investigator. There were
no statistically signiﬁcant demographic differences (i.e.,
gender, age, weight, and ethnicity) between the patients
who required a dose adjustment and those who did not.
Safety
Overall, 75.4% (n = 187) of the patients reported at least
one AE and of the total AEs, most were mild (49%) or
moderate (47%) in intensity, and 42.3% of the total were
considered by the investigator to be related to lubiprostone
(Table 2 summarizes the AEs reported by C5% of
patients). Of the total AEs broken down by body system,
the most common were gastrointestinal disorders (49.6%),
followed by infections/infestations (26.6%), disorders of
the nervous system (13.3%), and musculoskeletal and
connective-tissue disorders (12.9%). The AEs occurring as
severe in intensity and reported by C2 patients overall
were abdominal distension, abdominal pain, arthralgia,
back pain, neck pain, and nausea.
The majority of treatment-related AEs reported by
patients were of mild (50%) or moderate (44%) intensity.
Of the two most commonly reported AEs, nausea (19.8%)
and diarrhea (9.7%),[95% of these events were reported
as either mild or moderate in severity and none were
serious adverse events. In addition, the total number of
patient days during the study was 62,325 days, and nausea
and diarrhea event rates were 1.08 and 0.61 per 1,000
patient days, respectively.
Overall, a total of 33 patients (13.3%) withdrew from
the study due to AEs. Nausea accounted for 13 (5.2%)
withdrawals, of which approximately nine patients
(*70%) withdrew within the ﬁrst 12 weeks, ten ([75%)
by week 14, and all 13 (100%) by week 27. Other common
AEs that led to discontinuation were abdominal distension
(n = 5; 2.0%), headache (n = 4; 1.6%), abdominal pain
(n = 4; 1.6%), diarrhea (n = 3; 1.2%), and vomiting
(n = 3; 1.2%).
Eleven patients reported a total of 16 SAEs, of which
only one, a normal pregnancy resulting in a baby with
bilateral clubfoot, was considered possibly related to the
study drug by the investigator. This SAE is further
described in the discussion section. There were no deaths
during this study.
The average changes in vital signs, physical examina-
tion, and urinalysis parameters were not clinically signiﬁ-
cant. The mean hematology and biochemistry values and
the shifts in measurements did not show any clinically
signiﬁcant trends (data on ﬁle). Most notably, there were
no clinically meaningful trends in creatine kinase, alanine
transaminase (ALT), aspartate transaminase (AST), and
electrolyte (such as sodium, calcium, potassium, chloride,
and magnesium) concentrations [20]. Electrocardiographic
(ECG) changes were not measured in this study. Prior work
demonstrated no signiﬁcant ECG abnormalities or prolon-
gation of the QTc interval [21].
Patient-Reported Outcomes
Patients who received C1 dose of lubiprostone and had at
least 1 outcome evaluation (n = 248) were eligible for
outcome assessment. The mean patient-reported constipa-
tion severity score was 2.94 at baseline (0 = absent;
4 = very severe). Following initiation of lubiprostone
treatment, mean constipation severity scores were\2, and
remained at this level for the duration of treatment (Fig. 2).
Overall, the mean reduction in constipation severity at all
post-baseline time points was statistically signiﬁcant
(p\0.0015). Similar post-baseline reductions were
reported for mean abdominal bloating and discomfort
scores. Mean baseline scores for abdominal bloating and
discomfort were 2.10 and 1.88, respectively. After treat-
ment initiation, mean abdominal bloating scores
were B1.13 at all visits and\1 for weeks 18 and 30–48
(Fig. 2), increasing to 1.15 at study end. Mean abdominal
discomfort scores were\1 at every post-baseline assess-
ment, with a score of 0.98 at study end. Decreases
(improvements) in both abdominal bloating and discomfort
scores, at all time points post-baseline, were statistically
signiﬁcant (p B 0.011).
Mean patient global assessments of treatment effec-
tiveness (1 = a little bit effective; 4 = extremely effec-
tive) remained above 2 (moderately effective) for the entire
study, with median values ranging from 2–3 for all treat-
ment weeks.
Table 2 Most common adverse events experienced by C5% of
patient (safety-evaluable population)







n (%) n (%)
Nausea 52 (21.0) 49 (19.8)
Diarrhea 28 (11.3) 24 (9.7)
Headache 25 (10.1) 17 (6.9)
Abdominal distension 21 (8.5) 17 (6.9)
Urinary tract infection 17 (6.9) –
Abdominal Pain 15 (6.0) 13 (5.2)
a Includes events with a relationship to study medication of possibly,
probably, or deﬁnitely
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The short-term (4-week) effectiveness and safety of lubi-
prostone had been previously established in two placebo-
controlled trials in patients with chronic constipation [16,
17]. However, chronic constipation typically requires long-
term treatment. Therefore, it is important to establish the
long-term efﬁcacy and safety proﬁle of lubiprostone.
The mean daily capsule intake of 1.7/day indicated that
patients were generally compliant with BID dosing
throughout the 48-week study period. The study further
demonstrated that lubiprostone 24 mcg BID was generally
well tolerated by adult patients with chronic constipation.
The results were consistent with those observed during the
4-week chronic constipation trials [16, 17]. Nearly all
treatment-related AEs were of mild (51%) to moderate
(42%) intensity. The most common treatment-related AE
was nausea (19.8%), followed by diarrhea (9.7%), with
event rates of 1.08 and 0.61 per 1,000 patient-days,
respectively. Thirty-three patients (13.3%) withdrew from
the study due to AEs, of which 13 were due to nausea
(5.2%). It is notable that, although the current study com-
prised 48 treatment weeks, the percentage of patients
withdrawing from this study due to nausea (5.2%) was
similar to the percentages of patients discontinuing treat-
ment in the 4-week studies (approximately 5%) [16, 17].
Furthermore, since 70% of discontinuations due to nausea
in this long-term study were within the ﬁrst 12 weeks,
these results might suggest that patients who can tolerate
the drug initially may demonstrate successful long-term
outcomes. The mechanism responsible for nausea is
unknown, but has been hypothesized to involve an exag-
gerated pharmacodynamic effect from secreted ﬂuid in the
small intestine or a direct gastric effect resulting from a
lubiprostone-related modest delay in gastric emptying
(mean t1/2, 132.4 min lubiprostone vs. 106.1 min placebo)
[15]. In the current study, there were no clinically relevant
consequences from the patients who experienced diarrhea.
One SAE (out of 16 total in the trial) was assessed to be
possibly related to the study drug. The patient, a 27-year-
old female with no relevant medical history (concomitant
medications included diphenhydramine, paroxetine hydro-
chloride, bisacodyl, cortisone, and hydroxyzine) became
pregnant, approximately 8-1/2 months after enrollment
into the study. Because of her pregnancy, the patient dis-
continued participation in the study. Seven months later,
she gave birth to a healthy infant with bilateral clubfoot.
Including this case, there have been a total of six
reported pregnancies in clinical trials with lubiprostone.
Five of the six pregnancies were carried to term (the other
one was electively terminated) and no other fetal abnor-
malities were reported.
On average, the changes in serum electrolyte levels were
not clinically signiﬁcant. This ﬁnding suggests a more
physiologic laxation effect with lubiprostone when com-
pared to reports of clinically signiﬁcant electrolyte shifts
with some commercially available laxatives [7].
Long-term, open-label studies have inherent limitations
relating to the assessment of treatment efﬁcacy, particu-
larly in the areas of generalizability of the results to
unselected populations and patient attrition during the
study period. Nevertheless, there is some value in exam-
ining the patient-reported outcomes in this long-term study
population. Patients reported signiﬁcant improvements
from baseline in constipation severity and abdominal
symptoms. Signiﬁcant relief of these symptoms was
observed at the ﬁrst evaluation and was sustained
throughout all 48 weeks of the study, suggesting that
lubiprostone provided sustained relief of these symptoms
without leading to tachyphylaxis. Furthermore, evaluation
of patient satisfaction indicated that most patients rated
lubiprostone therapy as moderately effective or quite




lubiprostone 24 mcg BID. End
of treatment is deﬁned as the
last non-missing, post-baseline
treatment period value. Follow-
up is 2 weeks after end of
treatment
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signiﬁcant proportion of patients appeared satisﬁed with
their treatment as[50% of patients continued treatment for
the entire study period. These results are consistent with
other lubiprostone trials of shorter duration [16, 17].
Results from this long-term trial suggest that lubiprostone
remains safe and effective and provides consistent symp-
tom relief for 1 year in adult patients with chronic
constipation.
A limitation of the current study design was the lack of
blinding or a placebo control group. Placebo-controlled
studies of long duration are difﬁcult to perform due to the
high dropout rate of patients in the placebo arm [22].
However, despite the absence of a placebo arm, these
results indicate that the 48-week safety and effectiveness
results were consistent with those reported in the shorter-
term (i.e., 4 weeks) double-blinded, placebo-controlled
studies [16, 17].
In conclusion, the present study demonstrates that
lubiprostone may be considered safe and generally well
tolerated, with effectiveness consistently maintained across
48 weeks in adult patients with chronic constipation.
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